skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells

Abstract

Highlights: Black-Right-Pointing-Pointer EZH2 is overexpressed in the nuclei of renal cancer cells. Black-Right-Pointing-Pointer Nuclear EZH2 is associated with advanced stage and worse survival of RCC patients. Black-Right-Pointing-Pointer EZH2 is negatively regulated by miR-101 in renal cancer cells. Black-Right-Pointing-Pointer Depletion of EZH2 leads to re-expression of p27Kip1. Black-Right-Pointing-Pointer Reintroduction of miR-101 results in suppression of cell proliferation. -- Abstract: We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.

Authors:
;  [1];  [2]; ;  [1];  [3];  [1]
  1. Laboratory of Molecular Oncology, Department of Urology, Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585 (Japan)
  2. Tumor Biology Core, Center for Developmental Therapeutics, Chemistry of Life Processes Institute, Northwestern University, Silverman Hall B733, Evanston, IL (United States)
  3. Department of Human Pathology (Second Department of Pathology), Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585 (Japan)
Publication Date:
OSTI Identifier:
22207888
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 422; Journal Issue: 4; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; CARCINOMAS; CELL PROLIFERATION; INHIBITION; KIDNEYS; METHYL TRANSFERASES; PATIENTS

Citation Formats

Sakurai, Toshihiko, Bilim, Vladimir N., Ugolkov, Andrey V., E-mail: ugolkov@northwestern.edu, Yuuki, Kaori, Tsukigi, Masaaki, Motoyama, Teiichi, and Tomita, Yoshihiko, E-mail: ytomita@med.id.yamagata-u.ac.jp. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. United States: N. p., 2012. Web. doi:10.1016/J.BBRC.2012.05.035.
Sakurai, Toshihiko, Bilim, Vladimir N., Ugolkov, Andrey V., E-mail: ugolkov@northwestern.edu, Yuuki, Kaori, Tsukigi, Masaaki, Motoyama, Teiichi, & Tomita, Yoshihiko, E-mail: ytomita@med.id.yamagata-u.ac.jp. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. United States. doi:10.1016/J.BBRC.2012.05.035.
Sakurai, Toshihiko, Bilim, Vladimir N., Ugolkov, Andrey V., E-mail: ugolkov@northwestern.edu, Yuuki, Kaori, Tsukigi, Masaaki, Motoyama, Teiichi, and Tomita, Yoshihiko, E-mail: ytomita@med.id.yamagata-u.ac.jp. Fri . "The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells". United States. doi:10.1016/J.BBRC.2012.05.035.
@article{osti_22207888,
title = {The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells},
author = {Sakurai, Toshihiko and Bilim, Vladimir N. and Ugolkov, Andrey V., E-mail: ugolkov@northwestern.edu and Yuuki, Kaori and Tsukigi, Masaaki and Motoyama, Teiichi and Tomita, Yoshihiko, E-mail: ytomita@med.id.yamagata-u.ac.jp},
abstractNote = {Highlights: Black-Right-Pointing-Pointer EZH2 is overexpressed in the nuclei of renal cancer cells. Black-Right-Pointing-Pointer Nuclear EZH2 is associated with advanced stage and worse survival of RCC patients. Black-Right-Pointing-Pointer EZH2 is negatively regulated by miR-101 in renal cancer cells. Black-Right-Pointing-Pointer Depletion of EZH2 leads to re-expression of p27Kip1. Black-Right-Pointing-Pointer Reintroduction of miR-101 results in suppression of cell proliferation. -- Abstract: We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.},
doi = {10.1016/J.BBRC.2012.05.035},
journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 4,
volume = 422,
place = {United States},
year = {2012},
month = {6}
}